Clinical profile and long-term outcome of the first seizures in children

Pınar Arıcan1, Hakan Salman2, Nihal Olgaç Dündar3

  • 1Department of Pediatric Neurology, Kahramanmaraş Necip Fazil Hospital, Kahramanmaraş.

Insights

First seizures in children can lead to epilepsy, especially unprovoked seizures. Prompt diagnosis and treatment are crucial for managing pediatric seizure outcomes and preventing long-term conditions like epilepsy.

Area of Science:

  • Pediatric Neurology
  • Clinical Medicine
  • Epileptology

Background:

  • Seizures are a frequent reason for pediatric hospital admissions.
  • Understanding the clinical profile and outcomes of first-time seizures in children is critical.

Purpose of the Study:

  • To identify the clinical characteristics and outcomes of first seizures in children.
  • To differentiate outcomes based on seizure types: febrile, nonfebrile-provoked, and unprovoked seizures.

Main Methods:

  • A cohort of 138 children (1 month to 18 years) presenting with their first seizure was enrolled.
  • Patients were classified into three groups: febrile seizure, nonfebrile-provoked seizure, and unprovoked seizure.
  • Follow-up assessments were conducted at 18 months and 8 years to evaluate seizure recurrence and epilepsy development.

Main Results:

  • 60% of children experienced febrile seizures, 17% nonfebrile-provoked, and 40% unprovoked seizures.
  • Children with nonfebrile-provoked seizures did not develop epilepsy within 8 years.
  • A significant proportion (60% at 18 months, 82% at 8 years) of children with unprovoked seizures experienced recurrence, with higher rates in those with abnormal EEG and MRI findings.

Conclusions:

  • Provoked first seizures in children do not typically lead to epilepsy.
  • Unprovoked first seizures carry a substantial risk of recurrence and progression to epilepsy.
  • Identifying the underlying cause of seizures and initiating appropriate treatment is essential for managing pediatric epilepsy.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
385
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
706
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
539
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
44